Biomarker Panel for RA Cardiovascular and Infection Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the risk of cardiovascular disease (CVD) and serious infections in patients with inflammatory diseases like rheumatoid arthritis (RA) are inadequate, particularly in predicting risks for women and younger individuals, and there is a need for a test to evaluate vulnerability to serious infections in RA patients undergoing immunosuppressive therapies.
Innovation Solution
A method involving immunoassays to generate a risk score using specific protein biomarkers such as CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, and VEGFA, combined with clinical assessments, to predict the risk of CVD and infections in RA patients, and recommend appropriate therapeutic regimens based on these scores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional risk scores (Framingham and Reynolds) are used to assess CVD risk, then the assessment can be performed with basic clinical parameters, but the prediction accuracy is insufficient for women and younger individuals who are highly represented in RA populations
Solution Approach 1:
The patent segments the risk assessment into multiple independent biomarker components (12 specific serum proteins) rather than using a single composite score. This allows each biomarker to contribute independently to the overall MBDA score, improving prediction accuracy for specific subgroups like women and younger individuals while maintaining a structured, manageable assessment framework
Solution Approach 2:
The patent changes the parameters being measured from traditional clinical factors (age, gender, cholesterol, blood pressure) to a panel of 12 specific serum protein biomarkers. This parameter transformation enables more precise risk prediction by capturing inflammatory and metabolic pathways relevant to RA patients, particularly improving accuracy for underrepresented groups in traditional scoring systems
2Reliability
If immunosuppressive therapies are administered to RA patients to control disease activity, then disease symptoms are improved, but the risk of developing serious infections increases
Solution Approach 1:
The patent performs preliminary assessment of infection risk using the MBDA score before initiating or continuing immunosuppressive therapy. By evaluating 12 serum biomarkers that predict vulnerability to serious infections, clinicians can identify high-risk patients in advance and adjust treatment strategies proactively, preventing infections before they occur rather than reacting after therapy has already compromised immunity
Solution Approach 2:
The patent implements a feedback mechanism where MBDA scoring results inform clinical decisions about immunosuppressive therapy. The biomarker profile provides continuous feedback on a patient's vulnerability state, allowing dynamic adjustment of treatment intensity to balance disease control benefits against infection risks, thereby resolving the contradiction between effective disease management and infection prevention
3Reliability
If traditional clinical assessments are used to monitor RA disease activity, then the assessment process is simple, but the ability to predict serious outcomes like myocardial infarction and infection is limited
Solution Approach 1:
The patent merges 12 individual serum biomarker measurements into a single integrated MBDA score that simultaneously reflects multiple disease processes including inflammation, metabolism, and cardiovascular risk. This consolidation maintains clinical simplicity while incorporating comprehensive predictive information, allowing clinicians to assess multiple risks (infection, myocardial infarction, disease flares) through one unified metric rather than multiple separate assessments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate assessment of CVD and infection risks in RA patients, enabling personalized therapeutic decisions and improving management of RA by identifying high-risk individuals and tailoring treatment strategies.
Implementation Method 1
performing at least one immunoassay on a first blood sample from the subject to generate a first dataset comprising protein level data for at least two protein markers
Data Source
AI summary
Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.